Dr John J. Orloff, M.D., brings 25 years of global experience in clinical, drug discovery and development to the BenevolentAI Board. Previously, he served as Executive Vice President and Head of R&D at Alexion where he focused on strengthening Alexion’s clinical pipeline and research programs, enhancing R&D productivity, overseeing regulatory and medical affairs and supporting business development. Over a period of 3 years, Dr. Orloff led the expansion of the development pipeline from 3 to nearly 30 programs, spanning over 80 clinical trials from Phase 1 to Phase 4, and a significant increase in productivity from internal discovery research, with the delivery of 3 novel INDs. Dr Orloff served as EVP, Global Head of R&D, and CSO at Baxalta and SVP, Global Head of Clinical Development at Merck Serono. Dr Orloff served as CMO and SVP, Global Development and Novartis Pharmaceuticals and in executive positions with Merck Research Labs.
Dr Orloff received an undergraduate degree in chemistry from Dartmouth College and earned his medical degree from the University of Vermont, College of Medicine and completed a fellowship in endocrinology and metabolism at Yale University School of Medicine.
